An investigator-initiated clinical trial led by George Sakoulas, M.D., of Sharp Memorial Hospital in San Diego, studied the use of IVIg as a coronavirus pandemic treatment for adults experiencing respiratory failure. Supported by Octapharma USA, the research focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure, becoming dependent on ventilators.
Specifically, the study investigated whether or not IVIg treatment can halt COVID-19 progression to respiratory failure requiring patient transfer into intensive care and use of mechanical ventilation, and whether adding IVIg to the standard of care can reduce the number of days requiring oxygen therapy and the duration of hospital stay.
Want to learn more about the study and preliminary results? Watch Dr. Sakoulas’ video presentation: COVID-19 & IVIg Efficacy Preliminary Results: Can High-Dose IVIg Reverse Worsening of the Disease? At Which Stage Should it Be Administered?
Note: you must have an existing VuMedi account or register for a free account to view the video.
Watch Dr. Sakoulas present the final results:
In addition to pulmonary distress, severely and critically ill COVID-19 patients may develop myocardial dysfunction, specifically, elevated cardiac biomarkers and evidence of left ventricular (LV) damage. An investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Kentucky, is investigating the use of IVIg treatment and steroids as a possible treatment regimen for patients developing heart problems.